New immune combo takes on tough pancreatic cancer
NCT ID NCT07416240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of two immune cell therapies—dendritic cells and CAR-T cells—both engineered to target a protein called Claudin18.2 found on some pancreatic cancer cells. The goal is to see if this dual approach is safe and can shrink tumors in people with advanced pancreatic cancer. Only 10 participants will be enrolled, and the main focus is on side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Claudin18.2-targeted activated dendritic cells and CAR-T cells
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer by helping the immune system attack tumors more effectively.
What could go wrong
This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The approach is complex and may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hainan Cancer Hospital
RECRUITINGHaikou, Hainan, 570311, China
Contact Phone: •••-•••-•••• Email: •••••@•••••